A phase 1 study of the safety, pharmacokinetics, and pharmacodynamics of intermittent oral PRTX007, an IRF7-biased TLR7 agonist prodrug

Authors
Category Primary study
Conference2026 ASCO annual meeting
Year 2026
This article has no abstract
Epistemonikos ID: 81253fc4ee57cd77b54d1a338c8280d825e19ae4
First added on: Jul 04, 2026